Skin Substitute Categories: Understanding Product Types

Skin Substitute Categories: A Guide for Wound Care Clinicians

Skin substitutes — also called cellular and/or tissue-based products (CTPs) — are among the most effective advanced therapies available for chronic wounds that have failed to respond to standard care. However, the skin substitute categories landscape is complex. There are dozens of products on the market, derived from different tissue sources, processed in different ways, and classified under different CMS reimbursement categories. For wound care clinicians, understanding the product categories is essential for making appropriate clinical selections and navigating the billing requirements that apply to each type.

CMS restructured skin substitute reimbursement effective January 1, 2025, moving from product-specific Q-codes with individual pricing to a simplified category-based system. Understanding the current CMS product categories is now a core competency for wound care billing.

---

The Four Source Categories

All skin substitutes are derived from one of four tissue sources. The source determines the biological properties, regulatory pathway, and — to some extent — the clinical applications.

Autografts

Autografts use the patient's own tissue. In wound care, autologous skin grafts (split-thickness or full-thickness) are the gold standard for wound closure when donor sites are available.

Products and techniques:

• Split-thickness skin graft (STSG) — harvested with a dermatome from a donor site (typically thigh)
• Autologous platelet-rich plasma (PRP) — concentrated from the patient's own blood
• Autologous fat grafts — used in select chronic wound applications
• Epidermal skin grafts — harvested using suction blister technique (e.g., CelluTome)

Clinical considerations:

• No immunologic rejection risk
• Requires a suitable donor site, which creates a secondary wound
• Not classified under the CMS CTP payment categories — autologous grafts are billed under standard surgical CPT codes (15100-15136)
• PRP regulatory status varies by MAC

Allografts (Human Tissue)

Allografts are derived from human donor tissue — typically cadaveric dermis, amnion, or chorion. These are the largest product category in wound care.

Product examples:

• Amniotic membrane products: Dehydrated human amnion/chorion membrane (dHACM), cryopreserved products. Examples include EpiFix, Grafix, AmnioExcel.
• Acellular dermal matrices (ADM): Processed cadaveric dermis with cells removed, leaving the collagen scaffold. Examples include AlloDerm, DermaMatrix.
• Cellular allografts: Products containing viable human cells (fibroblasts, keratinocytes) in a matrix. Examples include Dermagraft, Apligraf.

Clinical considerations:

• No donor site morbidity
• Potential for immune-mediated rejection (mitigated by processing in acellular products)
• Subject to FDA regulation as human cells, tissues, and cellular/tissue-based products (HCT/Ps) under Section 361 or as biologics/devices
• Most commonly used CTPs in outpatient wound care

Xenografts (Animal Tissue)

Xenografts are derived from animal tissue, most commonly porcine (pig), bovine (cow), or ovine (sheep) sources.

Product examples:

• Porcine small intestinal submucosa (SIS): Oasis Wound Matrix, BioSIS
• Bovine collagen: Integra Dermal Regeneration Template (bilayer), PriMatrix (fetal bovine dermis)
• Ovine collagen scaffolds: Endoform Dermal Template
• Equine pericardium products: Select products in the surgical reconstruction space

Clinical considerations:

• No human donor required — consistent manufacturing and availability
• Cross-species immune response possible but generally well-tolerated after processing
• Collagen scaffolds serve as templates for tissue ingrowth rather than direct tissue replacement
• Some xenograft products are classified as devices rather than biologics, which affects the regulatory and reimbursement pathway

Synthetic Products

Synthetic skin substitutes are manufactured from non-biologic materials, often combined with growth factors or designed to mimic the extracellular matrix.

Product examples:

• Biobrane: Nylon mesh bonded to silicone with porcine collagen peptides (hybrid synthetic/xenograft)
• Hyaluronic acid-based scaffolds: Hyalomatrix
• Polyurethane scaffolds: NovoSorb BTM (biodegradable temporizing matrix)
• Collagen-glycosaminoglycan matrices: Integra (the bilayer version has both synthetic and xenograft components)

Clinical considerations:

• No immunologic concerns from human or animal tissue
• Consistent product properties with no donor variability
• Generally serve as scaffolds for tissue ingrowth rather than providing living cells
• Regulatory classification varies — some are devices, some are combination products

---

CMS Product Categories and the Flat Rate Structure

Effective January 1, 2025, CMS replaced the product-specific HCPCS Q-code pricing for skin substitutes with a category-based payment system. Products are assigned to categories based on their characteristics, and each category receives a flat reimbursement rate per square centimeter.

How the Category System Works

CMS assigns each skin substitute product to one of several product categories. The categories are determined by whether the product contains cells, whether it contains a scaffold or matrix component, and whether it is human-derived. The 2025/2026 flat rate is approximately $127.14 per square centimeter across the primary outpatient categories, though rates vary by category and are updated periodically.

What This Means for Product Selection

The flat rate per square centimeter means that product selection should be driven by clinical indication, not by reimbursement differential. Under the prior system, some products reimbursed significantly higher than others, creating financial incentives that did not always align with clinical appropriateness. The flat rate removes that distortion.

Clinically driven selection criteria:

• Wound type: DFUs, VLUs, pressure injuries, and surgical wounds each have different evidence bases for specific products
• Wound depth: Superficial wounds may respond to thin amniotic membrane products. Deep wounds with exposed tendon or bone may require thicker dermal matrices or bilayer products.
• Wound bed preparation: The wound must have a clean, granulating base before CTP application. A wound with >50% slough or necrotic tissue is not ready for a skin substitute.
• Patient factors: Allergy history (bovine, porcine, or specific product components), vascular status (ABI must be documented for lower extremity wounds), nutritional status, and ability to offload (for DFUs).
• LCD requirements: The applicable MAC LCD specifies documentation requirements that must be met before applying any CTP. This includes failure of standard wound care for a defined period (typically 30 days), wound measurements, and vascular assessment.

For detailed billing guidance on skin substitute Q-codes and application CPT codes, see Skin Substitute Billing Guide.

For the latest on CMS skin substitute coding changes, see Skin Substitute Coding Updates for 2026.

---

Application Frequency and LCD Compliance

Regardless of product category, LCD requirements govern how frequently skin substitutes can be applied and what documentation must support each application.

General LCD Requirements Across MACs

• Failure of standard care: Documentation of appropriate wound care for a defined period (typically 4 weeks/30 days) without adequate healing progress (<30% reduction in wound area)
• Vascular assessment: ABI for lower extremity wounds documented within the timeframe specified by the MAC (typically 90 days)
• Wound measurements: Length, width, depth in centimeters at each application visit
• Clean wound bed: Documentation that the wound bed is free of necrotic tissue, infection, and undermining at the time of application
• Offloading: For DFUs, documentation of an appropriate offloading device in use
• Nutritional optimization: Some MACs require documentation of nutritional assessment

Application Frequency

Most MACs allow skin substitute application at intervals of 1 to 2 weeks. The LCD specifies the maximum number of applications per wound episode. Exceeding the allowed applications without documented medical necessity justification will result in denial.

---

Key Takeaways

• Skin substitutes fall into four source categories — autograft, allograft, xenograft, and synthetic — each with distinct biological properties, regulatory classifications, and clinical applications.
• CMS replaced product-specific Q-code pricing with a flat-rate category system (approximately $127.14 per square centimeter), which means product selection should now be driven purely by clinical appropriateness, not reimbursement.
• Allografts (human tissue products including amniotic membranes and acellular dermal matrices) are the most commonly used CTPs in outpatient wound care.
• LCD compliance — including documented failure of standard care, vascular assessment, wound measurements, and clean wound bed — is required regardless of which product category is selected.
• Understanding the product categories helps clinicians match the right product to the wound characteristics: superficial wounds may respond to thin amniotic products, while deep wounds with exposed structures require thicker dermal matrices or bilayer constructs.